ArticleOPEN ACCESS

CD20 antibodies: Doing the time warp

Blood
DOI: 10.1182/blood-2011-04-346700
24Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

With the success of the anti-CD20 mAb rituximab in treating B-cell disorders from lymphoma through rheumatoid arthritis, anti-CD20 mAbs are now big business with as many as 16 biosimilars in clinical development.1 Understanding what makes CD20 such an ideal target and how to select new anti-CD20 mAbs is the subject of intense research.

Cite

CITATION STYLE

APA

Cragg, M. S. (2011, July 14). CD20 antibodies: Doing the time warp. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2011-04-346700

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free